Greatly Health Secures $4M Seed Funding to Scale MSK-Validated Integrative Oncology Platform

Why It Matters

By proving that non‑pharmacologic, virtual supportive care can drive survival gains and lower acute‑care costs, Greatly positions itself to become a reimbursable, value‑based offering in the $200 billion U.S. oncology market.

Key Takeaways

• Greatly Health raised $4M seed round led by Pear VC, Commonweal
• Platform validated at MSK shows 16% survival boost, 69% fewer hospitalizations
• Live group sessions cover exercise, nutrition, yoga, mindfulness with personalized coaching
• Goal: shift integrative oncology from charity model to reimbursed standard care
• Partnerships target 200 metastatic breast cancer patients, aiming for broader payer adoption

Pulse Analysis

Integrative oncology—combining nutrition, exercise, yoga, and mindfulness with conventional cancer treatment—has long been limited to academic centers and philanthropy‑funded programs. Greatly Health aims to close that access gap by delivering a fully virtual, expert‑led platform that can be scaled nationwide. Backed by a $4 million seed round co‑led by Pear VC and Commonweal Ventures, the startup leverages technology to bring group‑based supportive care into patients’ homes, positioning itself at the intersection of digital health and lifestyle medicine. The model’s scalability also aligns with recent CMS initiatives that fund lifestyle‑based research for Medicare beneficiaries.

In randomized trials at Memorial Sloan Kettering Cancer Center, Greatly’s program produced a 16 percent absolute increase in two‑year overall survival and cut hospitalizations by 69 percent, while reducing treatment disruptions by 42 percent. Those outcomes rival the efficacy signals of many newly approved oncology drugs, yet they are achieved through non‑pharmacologic interventions that also improve fatigue, pain, and depression. By keeping patients on their prescribed regimens and lowering acute‑care utilization, the platform delivers both clinical benefit and cost savings for value‑based care contracts. Such data positions Greatly for inclusion in clinical pathways and potential partnership with pharmaceutical sponsors seeking real‑world evidence.

The seed funding will be used to upgrade the virtual technology stack, expand the clinical team, and add evidence‑based therapies beyond the current exercise‑nutrition suite. Greatly is already collaborating with health plans, oncology providers, and a global life‑sciences partner to serve roughly 200 metastatic breast‑cancer patients, a foothold that can be leveraged for broader payer adoption. With U.S. oncology spending exceeding $200 billion annually, a 69 percent reduction in hospitalizations could translate into billions in avoided costs, making the company an attractive prospect for value‑based insurers and investors alike. Future rounds may target international expansion as similar gaps exist in Europe and Asia.

Deal Summary

Greatly Health announced a $4 million seed round co‑led by Pear VC and Commonweal Ventures to expand its MSK‑validated virtual integrative oncology platform. The funding will support scaling of live group sessions, technology enhancements, and broader clinical team growth, aiming to make supportive cancer therapies reimbursable and widely accessible.